Immunic Inc To Discuss Phase 2b CALDOSE-1 Maintenance Phase Data Call Transcript
Good morning. I would like to welcome you to Immunic's webcast to present the positive results from our Phase IIb CALDOSE-1 maintenance phase data of vidofludimus calcium in moderate-to-severe ulcerative colitis patients as well as updates on our IMU-935 and IMU-856 programs. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's webcast.
Speaking on the call are our Chief Executive Officer and President, Dr. Daniel Vitt and our Chief Medical Officer, Dr. Andreas Muehler. (Operator Instructions). And this event is being recorded. (Operator Instructions)
Before we begin, I would like to remind you that this presentation may contain forward-looking statements, such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here. Please note that these forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
